Literature DB >> 22434032

Physiological consequences of transient outward K+ current activation during heart failure in the canine left ventricle.

Jonathan M Cordeiro1, Kirstine Calloe, N Sydney Moise, Bruce Kornreich, Dana Giannandrea, José M Di Diego, Søren-Peter Olesen, Charles Antzelevitch.   

Abstract

BACKGROUND: Remodeling of ion channel expression is well established in heart failure (HF). We determined the extent to which I(to) is reduced in tachypacing-induced HF and assessed the ability of an I(to) activator (NS5806) to recover this current. METHOD AND
RESULTS: Whole-cell patch clamp was used to record I(to) in epicardial (Epi) ventricular myocytes. Epi- and endocardial action potentials were recorded from left ventricular wedge preparations. Right ventricular tachypacing-induced heart failure reduced I(to) density in Epi myocytes (Control=22.1±1.9pA/pF vs 16.1±1.4 after 2weeks and 10.7±1.4pA/pF after 5 weeks, +50mV). Current decay as well as recovery of I(to) from inactivation progressively slowed with the development of heart failure. Reduction of I(to) density was paralleled by a reduction in phase 1 magnitude, epicardial action potential notch and J wave amplitude recorded from coronary-perfused left ventricular wedge preparations. NS5806 increased I(to) (at +50mV) from 16.1±1.4 to 23.9±2.1pA/pF (p<0.05) at 2weeks and from 10.7±1.4 to 14.4±1.9pA/pF (p<0.05) in 5 weeks tachypaced dogs. NS5806 increased both fast and slow phases of I(to) recovery in 2 and 5-week HF cells and restored the action potential notch and J wave in wedge preparations from HF dogs.
CONCLUSIONS: The I(to) agonist NS5806 increases the rate of recovery and density of I(to), thus reversing the HF-induced reduction in these parameters. In wedge preparations from HF dogs, NS5806 restored the spike-and-dome morphology of the Epi action potential providing proof of principal that some aspects of electrical remodelling during HF can be pharmacologically reversed.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434032      PMCID: PMC3401930          DOI: 10.1016/j.yjmcc.2012.03.001

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  27 in total

1.  Effects of the renin-angiotensin system on the current I(to) in epicardial and endocardial ventricular myocytes from the canine heart.

Authors:  H Yu; J Gao; H Wang; R Wymore; S Steinberg; D McKinnon; M R Rosen; I S Cohen
Journal:  Circ Res       Date:  2000-05-26       Impact factor: 17.367

2.  Reduction of I(to) causes hypertrophy in neonatal rat ventricular myocytes.

Authors:  Zamaneh Kassiri; Carsten Zobel; The-Tin T Nguyen; Jeffery D Molkentin; Peter H Backx
Journal:  Circ Res       Date:  2002-03-22       Impact factor: 17.367

3.  Homogeneity of cardiac contraction despite physiological asynchrony of depolarization: a model study.

Authors:  R C P Kerckhoffs; P H M Bovendeerd; J C S Kotte; F W Prinzen; K Smits; T Arts
Journal:  Ann Biomed Eng       Date:  2003-05       Impact factor: 3.934

4.  Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle.

Authors:  Jonathan M Cordeiro; Lindsey Greene; Cory Heilmann; Daniel Antzelevitch; Charles Antzelevitch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-12-11       Impact factor: 4.733

Review 5.  Regulation of cardiac excitation-contraction coupling by action potential repolarization: role of the transient outward potassium current (I(to)).

Authors:  Rajan Sah; Rafael J Ramirez; Gavin Y Oudit; Dominica Gidrewicz; Maria G Trivieri; Carsten Zobel; Peter H Backx
Journal:  J Physiol       Date:  2003-01-01       Impact factor: 5.182

6.  Effect of the I(to) activator NS5806 on cloned K(V)4 channels depends on the accessory protein KChIP2.

Authors:  A Lundby; T Jespersen; N Schmitt; M Grunnet; S-P Olesen; J M Cordeiro; K Calloe
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

7.  Excitation-contraction coupling in human heart failure examined by action potential clamp in rat cardiac myocytes.

Authors:  Patricia J Cooper; Christian Soeller; Mark B Cannell
Journal:  J Mol Cell Cardiol       Date:  2010-04-27       Impact factor: 5.000

8.  Prevention of hypertrophy by overexpression of Kv4.2 in cultured neonatal cardiomyocytes.

Authors:  Carsten Zobel; Zameneh Kassiri; The-Tin T Nguyen; Yang Meng; Peter H Backx
Journal:  Circulation       Date:  2002-10-29       Impact factor: 29.690

9.  Extracellular proton depression of peak and late Na⁺ current in the canine left ventricle.

Authors:  Lisa Murphy; Danielle Renodin; Charles Antzelevitch; José M Di Diego; Jonathan M Cordeiro
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-06-17       Impact factor: 4.733

10.  Regulation of Kv4.3 current by KChIP2 splice variants: a component of native cardiac I(to)?

Authors:  Isabelle Deschênes; Deborah DiSilvestre; George J Juang; Richard C Wu; W Frank An; Gordon F Tomaselli
Journal:  Circulation       Date:  2002-07-23       Impact factor: 29.690

View more
  16 in total

1.  Regional variation of the inwardly rectifying potassium current in the canine heart and the contributions to differences in action potential repolarization.

Authors:  Jonathan M Cordeiro; Tanya Zeina; Robert Goodrow; Aaron D Kaplan; Lini M Thomas; Vladislav V Nesterenko; Jacqueline A Treat; Leo Hawel; Craig Byus; Glenna C Bett; Randall L Rasmusson; Brian K Panama
Journal:  J Mol Cell Cardiol       Date:  2015-04-15       Impact factor: 5.000

2.  Repolarization reserve evolves dynamically during the cardiac action potential: effects of transient outward currents on early afterdepolarizations.

Authors:  Thao P Nguyen; Neha Singh; Yuanfang Xie; Zhilin Qu; James N Weiss
Journal:  Circ Arrhythm Electrophysiol       Date:  2015-03-14

3.  Novel mechanism of transient outward potassium channel current regulation in the heart: implications for cardiac electrophysiology in health and disease.

Authors:  Michael S Bohnen; Vivek Iyer; Kevin J Sampson; Robert S Kass
Journal:  Circ Res       Date:  2015-05-08       Impact factor: 17.367

4.  Development of heart failure is independent of K+ channel-interacting protein 2 expression.

Authors:  Tobias Speerschneider; Søren Grubb; Artina Metoska; Søren-Peter Olesen; Kirstine Calloe; Morten B Thomsen
Journal:  J Physiol       Date:  2013-10-07       Impact factor: 5.182

5.  Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.

Authors:  Alexander Burashnikov; José M Di Diego; Hector Barajas-Martínez; Dan Hu; Andrew C Zygmunt; Jonathan M Cordeiro; N Sydney Moise; Bruce G Kornreich; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Heart Fail       Date:  2014-05-29       Impact factor: 8.790

6.  Tissue-specific effects of acetylcholine in the canine heart.

Authors:  Kirstine Calloe; Robert Goodrow; Søren-Peter Olesen; Charles Antzelevitch; Jonathan M Cordeiro
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-03       Impact factor: 4.733

7.  Modulation of the voltage-gated potassium channel (Kv4.3) and the auxiliary protein (KChIP3) interactions by the current activator NS5806.

Authors:  Walter G Gonzalez; Khoa Pham; Jaroslava Miksovska
Journal:  J Biol Chem       Date:  2014-09-16       Impact factor: 5.157

8.  Differential responses of rabbit ventricular and atrial transient outward current (Ito) to the Ito modulator NS5806.

Authors:  Hongwei Cheng; Mark B Cannell; Jules C Hancox
Journal:  Physiol Rep       Date:  2017-03

9.  Repolarization Alternans and Ventricular Arrhythmia in a Repaired Tetralogy of Fallot Animal Model.

Authors:  Shuenn-Nan Chiu; Chia-Ti Tsai; Lian-Yu Lin; Shu-Chien Huang; Yih-Sharng Chen; Jou-Kou Wang; Mei-Hwan Wu; Ling-Ping Lai; Jiunn-Lee Lin
Journal:  J Am Heart Assoc       Date:  2015-12-11       Impact factor: 5.501

10.  Myocardial KChIP2 Expression in Guinea Pig Resolves an Expanded Electrophysiologic Role.

Authors:  Drew M Nassal; Xiaoping Wan; Haiyan Liu; Isabelle Deschênes
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.